Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 10/24 10:00:16 pm
60.75 USD   -0.74%
03:25aDJMERCK : Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
02:36aDJMERCK : Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
12:05a MERCK : FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Meta..
News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : WSJ BLOG/Health : Experimental Drug Might Open New Category of Sleep Aid

share with twitter share with LinkedIn share with facebook
share via e-mail
06/13/2012 | 06:17pm CEST

(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.)

By Christopher Weaver

Patients with severe insomnia taking a Merck experimental sleep drug drifted off faster and slept longer than those taking placebos in two clinical studies discussed at a Boston sleep conference today.

The drug, suvorexant, opens a new category of sleep drugs by blocking orexin, the brain's chemical emissaries that promote alertness. Merck says it plans to apply for FDA approval later this year.

Both of Merck's trials included more than 1,000 patients with insomnia. Patients whose sleep troubles were caused by other medical problems weren't included in the studies. The results were reported after three months of taking the drug or a placebo.

Those taking suvorexant reported falling asleep 25.7 minutes faster than usual, and sleeping an hour longer in one trial. Merck's researchers also observed patients in sleep labs and determined that patients taking the drug fell asleep 36 minutes faster than usual, while those taking placebos fell asleep 26.6 minutes faster.

The second trial also showed the drug helped people sleep longer, though people in that group who took it didn't fall asleep faster than patients taking placebos.

The findings were presented at the Sleep 2012, an annual meeting of sleep scientists and health providers.

The U.S. market for sleep drugs sagged to $1.85 billion in 2011, down about 8% from the prior year, according to IMS Health, a health-care-information company. The decline was driven by generic competition for key sleep drugs.

Suvorexant could offer a new option for patients with chronic insomnia who routinely need sleeping pills, Merck hopes. Other sleep drugs on the market, such as Ambien, keep patients asleep for about two thirds of the night, while suvorexant provides longer rest, Dr. Darryle Schoepp, Merck's vice president in charge of neuroscience, said in an interview last week.

For decades, a series of sleep drugs have focused on "shutting down the whole brain in maybe a less natural way," Schoepp said. So-called Gaba agonists, such as Ambien, Sonata and Lunesta, which are often prescribed to be taken as needed, have been shown to have side effects, including sleep walking, in a small fraction of patients.

Merck says patients who routinely need sleep aids will better tolerate suvorexant, which also performed well in a cohort of patients Merck followed for a full year. In contrast to older drugs, Schoepp said, Merck's research showed that patients taking suvorexant experienced normal sleep rhythm.

The study showed suvorexant's main side effects were headaches and morning drowsiness.

 -For continuously updated news from The Wall Street Journal, see WSJ.com at http://wsj.com. 

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK & CO., INC.
03:25aDJMERCK : Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
02:36aDJMERCK : Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
12:05a MERCK : FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Metastatic NSCLC..
10/24 MERCK : Seminole Management Co. Inc. Invests $19,783,000 in Merck & Co. (MRK)
10/24 GSK files potential $1 billion shingles vaccine for U.S. approval
10/22 MERCK : FDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to Reduce Recu..
10/21 MERCK : ’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Blad..
10/20 MERCK : New Findings from Merck & Company Describe Advances in Clinical Trials a..
10/20 MERCK : Findings on Pneumonia Reported by Researchers at Merck & Company (Ceftol..
10/20 NEW PEPTIDE HYDROLASES STUDY RESULTS : Improving Aqueous Solubility...
More news
Sector news : Pharmaceuticals - NEC
11:41aDJGerman Companies Cling to Cash as Outlook Sours
09:39aDJNOVARTIS : Profit Helped by GlaxoSmithKline Joint Venture -- Update
03:25aDJMERCK : Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
10/24DJGLAXOSMITHKLINE : 3Q 2016 -- Forecast
10/24DJSyngenta and ChemChina Miss EU Deadline for Antitrust Remedies
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/24 FDA OKs new indication for Merck's cancer med Keytruda
10/24 Notable earnings before Tuesday?s open
10/24 BIOTECH FORUM DAILY DIGEST : Election Worries Overblown? Spotlight On Akorn
10/24 Glaxo submits BLA for shingles vaccine in U.S.
10/22 FDA OKs Merck's bezlotoxumab to reduce recurrence of C. diff infection in cer..
Financials ($)
Sales 2016 39 697 M
EBIT 2016 13 611 M
Net income 2016 5 663 M
Debt 2016 5 348 M
Yield 2016 2,99%
P/E ratio 2016 29,67
P/E ratio 2017 19,65
EV / Sales 2016 4,37x
EV / Sales 2017 4,26x
Capitalization 167 986 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 68,0 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.15.01%167 986
JOHNSON & JOHNSON10.60%310 823
ROCHE HOLDING LTD.-15.88%200 485
NOVARTIS AG-13.71%197 285
PFIZER INC.-0.46%194 889
More Results